The World Health Organization recommendation, issued in October 2021, of broad use of the RTS,S/AS01 malaria vaccine among children living in regions with moderate to high Plasmodium falciparum transmission, the first such recommendation for a malaria vaccine. The vaccine has been shown to significantly reduce malaria, and deadly severe malaria, among young children. A second safe and effective vaccine, R21/Matrix-M, was recommended in October 2023, and the vaccines are being rolled out in routine childhood immunization programmes across Africa, where they are expected to save tens of thousands of young lives each year, with the highest impact when introduced alongside other recommended interventions such as bed nets.
Facts
Milestone Year Milestone Date Classification
Type/ClassificationTechnological Innovation 1 Connections
Associated With
The vaccines reach their highest impact when introduced alongside other recommended malaria interventions such as bed nets.
Source World Health Organization Official Site
Source World Health Organization Official Site
In Branch
In the Other Atlases
Found In
Also in Geography Atlas: where this subject is found.
Sources
1. World Health Organization Official Site
World Health OrganizationMalaria fact sheet
Since October 2021, WHO has recommended broad use of the RTS,S/AS01 malaria vaccine among children living in regions with moderate to high P. falciparum malaria transmission.
News item dated 6 October 2021, opening paragraph
WHO recommends widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa.
WHO news release, 6 October 2021
The World Health Organization (WHO) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission.
Program classification, entity description sentence
The World Health Organization recommendation, issued in October 2021, of broad use of the RTS,S/AS01 malaria vaccine among children living in regions with moderate to high Plasmodium falciparum transmission, the first such recommendation for a malaria vaccine.
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.